Developer docs
API playgroundTry for free, no card

Search company profiles

ALX Oncology

Full company profile

uuid0002cr6

Namestring
ALX Oncology
Legal namestring
ALX Oncology Inc.
Websiteurl
alxoncology.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

ALX Oncology is a clinical-stage biopharmaceutical company developing two investigational immuno-oncology therapies: evorpacept (ALX148), a CD47-blocking fusion protein engineered with an inactive Fc domain to minimize dose-limiting toxicities seen in earlier CD47 approaches, and ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) built on a proprietary linker-payload platform. Evorpacept has been evaluated in more than 750 patients across multiple Phase 1 and Phase 2 trials spanning HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, head and neck squamous cell carcinoma, multiple myeloma, and non-Hodgkin lymphoma, with a well-tolerated safety profile and notable efficacy signals including 100% objective response rate in HER2+ breast cancer patients with high CD47 expression (when combined with zanidatamab) and 92% complete response rate in indolent NHL (when combined with rituximab and lenalidomide). ALX2004 targets EGFR-expressing solid tumors including NSCLC, colorectal, and head and neck cancers, and is built on technology acquired in the October 2021 ScalmiBio acquisition.

The company operates a pre-revenue business model with no commercialized products and no product pricing. Revenue mechanics are entirely prospective: future income would derive from commercialization of approved therapies or from partnership upfront/milestone economics. Currently, capital is raised via equity and debt financings, including a $150M equity offering in early 2026 (led by RA Capital and TCGX) and a $100M debt facility from Oxford Finance and Silicon Valley Bank in 2022, with $169.1M cash on hand at end of Q1 2026 providing runway into H1 2028. The go-to-market motion is partnership-driven: Jazz Pharmaceuticals, Sanofi, and Lilly each sponsor trials combining evorpacept with their own agents (zanidatamab, SARCLISA, CYRAMZA respectively), creating embedded clinical activity without full internal trial cost. End customers are oncology patients across multiple solid tumor and hematologic indications, served through clinical trial sites globally.

Founded in 2015 and headquartered in South San Francisco, California, ALX Oncology is publicly traded on NASDAQ (ALXO) and led by a management team and board with deep biopharmaceutical operating experience, including CEO Jason Lettmann (former Lightstone Ventures General Partner; CEO of Promedior through Roche acquisition), CFO Harish Shantharam (ex-CymaBay/Gilead), CMO Barbara Klencke (ex-Sierra Oncology/Onyx), and CDOO Jeff Knight (ex-Crinetics/Amgen/Genentech). The Scientific Advisory Board is chaired by Dr. Keith Flaherty (Harvard/MGH, co-founder of Loxo Oncology).

Short descriptiontext

ALX Oncology is a clinical-stage biopharmaceutical company developing evorpacept, a CD47-blocking immuno-oncology therapy, and ALX2004, an EGFR-targeted antibody-drug conjugate, for solid tumor and hematologic cancer indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CD47 immunotherapy, immuno-oncology therapeutics, antibody-drug conjugates, clinical-stage biopharmaceutical, cancer drug development
Industry2 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-Revenue / Clinical Stage
TypeOne Time License
Description

ALX Oncology is a clinical-stage biotechnology company with no commercialized products and no revenue. The company is focused on developing its pipeline of cancer therapies through clinical trials. Future revenue would come from commercialization of evorpacept and ALX2004 upon regulatory approval.

stocktitan.net
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ALX Oncology is a clinical-stage biopharmaceutical company developing two investigational immuno-oncology therapies: evorpacept (ALX148), a CD47-blocking agent with an inactive Fc domain designed to enable innate immune destruction of cancer cells, and ALX2004, an EGFR-targeted antibody-drug conjugate using a topoisomerase I inhibitor payload for EGFR-expressing solid tumors. Both candidates are in clinical development and not yet approved for commercial sale.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 100% objective response rate in HER2+ metastatic breast cancer patients with high CD47 expression (>20%) treated with evorpacept plus zanidatamab, with 22.1 months median progression-free survival
+2 more records
Product overview1 text field

ALX Oncology is a clinical-stage biopharmaceutical company advancing a pipeline of two investigational cancer therapies: evorpacept (ALX148), a CD47-blocking agent being evaluated across multiple solid tumor and hematologic cancer indications in combination with anti-cancer antibodies, and ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) for EGFR-expressing solid tumors. Both candidates are in clinical development stages and have not been approved by regulatory authorities.

Product and service2 records
1Evorpacept (ALX148)
CategoryImmuno-oncology / CD47 antagonist
Description

Novel, highly differentiated CD47-blocking investigational therapy that blocks the 'don't eat me' signal transmitted by CD47 on the surface of cancer cells, enabling the innate immune system to recognize and destroy cancer cells. Features an inactive Fc domain that minimizes dose-limiting toxicities seen with previous CD47-blocking approaches. Being evaluated across HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, head and neck squamous cell carcinoma, multiple myeloma, non-Hodgkin lymphoma, and other indications.

2ALX2004
CategoryAntibody-Drug Conjugate / Oncology
Description

Novel EGFR-targeted antibody-drug conjugate (ADC) designed with a matuzumab-derived antibody stably linked to a topoisomerase I inhibitor (TOP1i) payload with a DAR of 8. Uses a proprietary linker-payload platform intended to minimize off-tumor skin toxicity and maximize the therapeutic window in EGFR-expressing solid tumors including non-small cell lung cancer, colorectal cancer, and head and neck cancers.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Jazz Pharmaceuticals and ALX Oncology are collaborating to conduct the zanidatamab/evorpacept clinical trial. This is a Phase 1b/2, 2-part open-label study to assess the safety and antitumor activity of zanidatamab in combination with evorpacept in patients with advanced HER2-expressing cancer. ALX Oncology retains worldwide rights to evorpacept in all indications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sanofi conducts and sponsors SARCLISA clinical trials while ALX Oncology supplies evorpacept. This is a Phase 1/2 clinical study evaluating evorpacept in combination with Sarclisa (isatuximab) in relapsed refractory multiple myeloma.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Lilly supplies CYRAMZA (ramucirumab) for ALX Oncology's ASPEN-06 program which evaluates evorpacept in combination with trastuzumab, CYRAMZA, and paclitaxel in patients with advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs), combining ADCs with innate immune agonism. Comparable to ALX Oncology's strategy of pairing tumor-targeting antibodies with immune activation.

TypeDirect peer
Description

Developed CD47-blocking therapeutics (SIRPαFc fusion proteins) for oncology before being acquired by Pfizer in 2022 for ~$2.3B. Directly comparable as a CD47-pathway oncology biotech at a similar clinical-development stage to ALX Oncology.

TypeDirect peer
Description

Pioneered CD47-targeting therapy with magrolimab and was acquired by Gilead Sciences for $4.9B in 2020. Most direct historical peer to ALX Oncology given shared CD47 mechanism and combination-development strategy in hematologic and solid tumors.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing novel antibody therapeutics targeting myeloid and immune checkpoints. Comparable to ALX Oncology given shared focus on innate immune engagement and combination oncology approaches.

TypeBroad incumbent
Description

Pioneer in ADC technology (developed trastuzumab deruxtecan with Daiichi Sankyo) acquired by AbbVie in 2024 for ~$10.1B. Relevant broad incumbent comparable to ALX Oncology's ADC ambitions given deep linker-payload expertise.

TypeEmerging player
Description

Clinical-stage ADC developer with proprietary linker-payload platforms (Dolasynthen, Immunosynthen) targeting oncology indications. Directly comparable to ALX's ADC strategy with ALX2004 given similar platform-driven ADC approach.

TypeEmerging player
Description

Clinical-stage biotech developing HER2-targeted bispecifics (zanidatamab), partnered with Jazz Pharmaceuticals — the same partner collaborating with ALX on zanidatamab + evorpacept. Directly comparable given overlapping clinical combination being tested.

TypeEmerging player
Description

Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies, including EGFR and HER2-targeted ADCs. Comparable to ALX Oncology given overlapping ADC target space (e.g., EGFR) and combination-therapy focus.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing combination regimens including checkpoint inhibitors and adenosine-pathway antagonists. Comparable to ALX Oncology given parallel focus on combination oncology strategies and big-pharma co-development partnerships (Gilead).

10IGM Biosciences
TypeEmerging player
Description

Clinical-stage biotech developing engineered IgM antibodies for oncology, including CD47-targeting and DR5 programs. Connected to ALX Oncology via board member Chris Takimoto (former CMO of IGM) and shared oncology biologics focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ALX Oncology

Immuno-oncology Therapeuticsalxoncology.com

ALX Oncology is a clinical-stage biopharmaceutical company developing evorpacept, a CD47-blocking immuno-oncology therapy, and ALX2004, an EGFR-targeted antibody-drug conjugate, for solid tumor and hematologic cancer indications.

What ALX Oncology does

ALX Oncology is a clinical-stage biopharmaceutical company developing two investigational immuno-oncology therapies: evorpacept (ALX148), a CD47-blocking fusion protein engineered with an inactive Fc domain to minimize dose-limiting toxicities seen in earlier CD47 approaches, and ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) built on a proprietary linker-payload platform. Evorpacept has been evaluated in more than 750 patients across multiple Phase 1 and Phase 2 trials spanning HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, head and neck squamous cell carcinoma, multiple myeloma, and non-Hodgkin lymphoma, with a well-tolerated safety profile and notable efficacy signals including 100% objective response rate in HER2+ breast cancer patients with high CD47 expression (when combined with zanidatamab) and 92% complete response rate in indolent NHL (when combined with rituximab and lenalidomide). ALX2004 targets EGFR-expressing solid tumors including NSCLC, colorectal, and head and neck cancers, and is built on technology acquired in the October 2021 ScalmiBio acquisition.

The company operates a pre-revenue business model with no commercialized products and no product pricing. Revenue mechanics are entirely prospective: future income would derive from commercialization of approved therapies or from partnership upfront/milestone economics. Currently, capital is raised via equity and debt financings, including a $150M equity offering in early 2026 (led by RA Capital and TCGX) and a $100M debt facility from Oxford Finance and Silicon Valley Bank in 2022, with $169.1M cash on hand at end of Q1 2026 providing runway into H1 2028. The go-to-market motion is partnership-driven: Jazz Pharmaceuticals, Sanofi, and Lilly each sponsor trials combining evorpacept with their own agents (zanidatamab, SARCLISA, CYRAMZA respectively), creating embedded clinical activity without full internal trial cost. End customers are oncology patients across multiple solid tumor and hematologic indications, served through clinical trial sites globally.

Founded in 2015 and headquartered in South San Francisco, California, ALX Oncology is publicly traded on NASDAQ (ALXO) and led by a management team and board with deep biopharmaceutical operating experience, including CEO Jason Lettmann (former Lightstone Ventures General Partner; CEO of Promedior through Roche acquisition), CFO Harish Shantharam (ex-CymaBay/Gilead), CMO Barbara Klencke (ex-Sierra Oncology/Onyx), and CDOO Jeff Knight (ex-Crinetics/Amgen/Genentech). The Scientific Advisory Board is chaired by Dr. Keith Flaherty (Harvard/MGH, co-founder of Loxo Oncology).

ALX Oncology firmographics

Firmographics
Name
ALX Oncology
Legal name
ALX Oncology Inc.
Website
https://alxoncology.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
ALX Oncology is a clinical-stage biopharmaceutical company developing evorpacept, a CD47-blocking immuno-oncology therapy, and ALX2004, an EGFR-targeted antibody-drug conjugate, for solid tumor and hematologic cancer indications.
Ownership category
akta.pro rank

ALX Oncology industry classification

Industry
Product category
Immuno-oncology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • CD47 immunotherapy
  • Immuno-oncology therapeutics
  • Antibody-drug conjugates
  • Clinical-stage biopharmaceutical
  • Cancer drug development

Where ALX Oncology is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ALX Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pre-Revenue / Clinical Stage: ALX Oncology is a clinical-stage biotechnology company with no commercialized products and no revenue. The company is focused on developing its pipeline of cancer therapies through clinical trials. Future revenue would come from commercialization of evorpacept and ALX2004 upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

ALX Oncology product offering

Product offering

Core offering

ALX Oncology is a clinical-stage biopharmaceutical company developing two investigational immuno-oncology therapies: evorpacept (ALX148), a CD47-blocking agent with an inactive Fc domain designed to enable innate immune destruction of cancer cells, and ALX2004, an EGFR-targeted antibody-drug conjugate using a topoisomerase I inhibitor payload for EGFR-expressing solid tumors. Both candidates are in clinical development and not yet approved for commercial sale.

Product overview

ALX Oncology is a clinical-stage biopharmaceutical company advancing a pipeline of two investigational cancer therapies: evorpacept (ALX148), a CD47-blocking agent being evaluated across multiple solid tumor and hematologic cancer indications in combination with anti-cancer antibodies, and ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) for EGFR-expressing solid tumors. Both candidates are in clinical development stages and have not been approved by regulatory authorities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Evorpacept (ALX148) Novel, highly differentiated CD47-blocking investigational therapy that blocks the 'don't eat me' signal transmitted by CD47 on the surface of cancer cells, enabling the innate immune system to recognize and destroy cancer cells. Features an inactive Fc domain that minimizes dose-limiting toxicities seen with previous CD47-blocking approaches. Being evaluated across HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, head and neck squamous cell carcinoma, multiple myeloma, non-Hodgkin lymphoma, and other indications.
  • ALX2004 Novel EGFR-targeted antibody-drug conjugate (ADC) designed with a matuzumab-derived antibody stably linked to a topoisomerase I inhibitor (TOP1i) payload with a DAR of 8. Uses a proprietary linker-payload platform intended to minimize off-tumor skin toxicity and maximize the therapeutic window in EGFR-expressing solid tumors including non-small cell lung cancer, colorectal cancer, and head and neck cancers.

Quantifiable outcome

  • 100% objective response rate in HER2+ metastatic breast cancer patients with high CD47 expression (>20%) treated with evorpacept plus zanidatamab, with 22.1 months median progression-free survival
  • +2 more outcomes

Companies that use ALX Oncology

Customer profile

Segments1 record

Ideal customer profiles3 records

ALX Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ALX Oncology partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Jazz PharmaceuticalscoreStrategic or Co-development PartnerJazz Pharmaceuticals and ALX Oncology are collaborating to conduct the zanidatamab/evorpacept clinical trial. This is a Phase 1b/2, 2-part open-label study to assess the safety and antitumor activity of zanidatamab in combination with evorpacept in patients with advanced HER2-expressing cancer. ALX Oncology retains worldwide rights to evorpacept in all indications.
  • SanoficoreStrategic or Co-development PartnerSanofi conducts and sponsors SARCLISA clinical trials while ALX Oncology supplies evorpacept. This is a Phase 1/2 clinical study evaluating evorpacept in combination with Sarclisa (isatuximab) in relapsed refractory multiple myeloma.
  • LillyminorStrategic or Co-development PartnerLilly supplies CYRAMZA (ramucirumab) for ALX Oncology's ASPEN-06 program which evaluates evorpacept in combination with trastuzumab, CYRAMZA, and paclitaxel in patients with advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

ALX Oncology competitors and assessment

Company assessment

Emerging players

  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs), combining ADCs with innate immune agonism. Comparable to ALX Oncology's strategy of pairing tumor-targeting antibodies with immune activation.
  • Compugen: Clinical-stage immuno-oncology company developing novel antibody therapeutics targeting myeloid and immune checkpoints. Comparable to ALX Oncology given shared focus on innate immune engagement and combination oncology approaches.
  • Mersana Therapeutics: Clinical-stage ADC developer with proprietary linker-payload platforms (Dolasynthen, Immunosynthen) targeting oncology indications. Directly comparable to ALX's ADC strategy with ALX2004 given similar platform-driven ADC approach.
  • Zymeworks: Clinical-stage biotech developing HER2-targeted bispecifics (zanidatamab), partnered with Jazz Pharmaceuticals — the same partner collaborating with ALX on zanidatamab + evorpacept. Directly comparable given overlapping clinical combination being tested.
  • Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies, including EGFR and HER2-targeted ADCs. Comparable to ALX Oncology given overlapping ADC target space (e.g., EGFR) and combination-therapy focus.
  • Arcus Biosciences: Clinical-stage immuno-oncology company developing combination regimens including checkpoint inhibitors and adenosine-pathway antagonists. Comparable to ALX Oncology given parallel focus on combination oncology strategies and big-pharma co-development partnerships (Gilead).
  • IGM Biosciences: Clinical-stage biotech developing engineered IgM antibodies for oncology, including CD47-targeting and DR5 programs. Connected to ALX Oncology via board member Chris Takimoto (former CMO of IGM) and shared oncology biologics focus.

Direct peers

  • Trillium Therapeutics: Developed CD47-blocking therapeutics (SIRPαFc fusion proteins) for oncology before being acquired by Pfizer in 2022 for ~$2.3B. Directly comparable as a CD47-pathway oncology biotech at a similar clinical-development stage to ALX Oncology.
  • Forty Seven, Inc. Pioneered CD47-targeting therapy with magrolimab and was acquired by Gilead Sciences for $4.9B in 2020. Most direct historical peer to ALX Oncology given shared CD47 mechanism and combination-development strategy in hematologic and solid tumors.

Broad incumbents

  • ImmunoGen: Pioneer in ADC technology (developed trastuzumab deruxtecan with Daiichi Sankyo) acquired by AbbVie in 2024 for ~$10.1B. Relevant broad incumbent comparable to ALX Oncology's ADC ambitions given deep linker-payload expertise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

ALX Oncology social profiles

Digital presence

ALX Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ALX Oncology leadership team

Management profile

Number of profiles

Profiles12 records

ALX Oncology funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ALX Oncology M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALX Oncology

What does ALX Oncology do?

ALX Oncology is a clinical-stage biopharmaceutical company developing two investigational immuno-oncology therapies: evorpacept (ALX148), a CD47-blocking agent with an inactive Fc domain designed to enable innate immune destruction of cancer cells, and ALX2004, an EGFR-targeted antibody-drug conjugate using a topoisomerase I inhibitor payload for EGFR-expressing solid tumors. Both candidates are in clinical development and not yet approved for commercial sale.

Is ALX Oncology a public or private company?

ALX Oncology is a public company. It is classified as public and is currently operating.

When was ALX Oncology founded?

ALX Oncology was founded in 2015. It employs 51 to 100 people.

Where is ALX Oncology based?

ALX Oncology is headquartered in South San Francisco, United States, in the North America region.

How does ALX Oncology make money?

One revenue line is on record: pre-Revenue / Clinical Stage.

Who are ALX Oncology's main competitors?

Emerging players on record are Bolt Biotherapeutics, Compugen, Mersana Therapeutics, Zymeworks, Pyxis Oncology, Arcus Biosciences and IGM Biosciences. Direct peers are Trillium Therapeutics and Forty Seven, Inc.. ImmunoGen is listed as a broad incumbent.

Does ALX Oncology have an API?

No public API is recorded for ALX Oncology.

What industry is ALX Oncology in?

ALX Oncology's product category is Immuno-oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comALX Oncology at Jefferies Global Healthcare Conference: data push aheadALX Oncology presented its two-pronged strategy at Jefferies, highlighting over 800 patients dosed with evorpacept and a planned 120-patient breast cancer update in H2 2025. For ALX2004, dosing has advanced beyond 4 mg/kg, with a data readout on 35-40 patients expected, targeting a response rate above 20% in a fourth-line setting.MarketScreenerALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026ALX Oncology Holdings reported a net loss of $57.72 million for the nine months ended September 30, 2026, down from $78.85 million a year earlier. Basic and diluted loss per share from continuing operations were $0.45 each, compared to $1.48 a year ago.Quiver QuantitativeALX Oncology Reports $21.8 Million Third-Quarter 2026 Net Loss | ALXO Stock NewsALX Oncology reported a GAAP net loss of $21.8 million for the third quarter ended September 30, 2026, with cash, cash equivalents and investments totaling $147.2 million. The company expects safety and early efficacy data from its Phase 1 ALX2004 study in December 2026 and topline data from approximately 120 patients in the Phase 2 ASPEN-09-Breast trial in the second half of 2027.American Banking and Market NewsALX Oncology (NASDAQ:ALXO) Rating Lowered to Sell at Wall Street ZenWall Street Zen downgraded ALX Oncology from hold to sell, while Weiss Ratings raised it from sell (e+) to sell (d-). The stock opened at $1.04, with an average analyst rating of Moderate Buy and a target price of $4.75. Institutional investors own 97.97% of the company.Business & FinancialGastric Cancer Market To Expand Rapidly By 2035 Amid Increasing Investments And Innovation Astrazeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma, Beigene, Zymeworks, ALX OncologyDelveInsight's report forecasts rapid growth in the gastric cancer market through 2034, citing rising disease burden and pipeline innovations. Key clinical results include durvalumab plus FLOT improving survival by 22% and zanidatamab's FDA approval for HER2-positive gastric cancer. The market is expected to expand due to increasing prevalence and awareness.MarketBeatALX Oncology (ALXO) Set to Post Earnings on FridayALX Oncology is set to report Q3 2026 earnings on Friday, November 6th, with analysts expecting a loss of $0.15 per share. The company previously beat estimates with a $0.13 loss, and analysts forecast a $0.59 loss for the current fiscal year. Weiss Ratings upgraded the stock to a sell (d-) rating.American Banking and Market NewsALX Oncology (ALXO) Set to Announce Quarterly Earnings on FridayALX Oncology is set to announce Q3 2026 earnings on Friday, November 6th, with analysts expecting a loss of $0.15 per share. The company previously reported a $0.13 loss for the prior quarter, beating the consensus estimate. Analysts have an average rating of Moderate Buy with a price target of $4.60.MarketBeatALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock Has Consensus Target Price of $4.60 According to AnalystsAnalysts rate ALX Oncology a Moderate Buy with an average target price of $4.60. Weiss Ratings raised its rating to sell (d-), and institutional investors own 97.97% of the stock. The company reported a loss of $0.13 per share for the quarter, beating estimates.TradingViewALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants With Key HoldersALX Oncology exchanged 13.35 million shares for pre-funded warrants with Blackstone, RA Capital, and venBio, settling on Oct 15, 2026. The warrants have no expiration and include ownership blockers up to 19.99%. The transactions aim to optimize capital structure and manage ownership thresholds.The future of tradingALX Oncology Exchanges 13,353,384 Common Shares for Pre-Funded WarrantsALX Oncology agreed to exchange 13,353,384 common shares for pre-funded warrants on October 14, 2026, with settlement expected on October 15, 2026. The warrants have a $0.001 exercise price and are subject to ownership caps of 4.99% or 9.99%, which can be raised to 19.99% after 61 days.